Victory Capital Management Inc. Decreases Stock Holdings in Integer Holdings Corporation (NYSE:ITGR)

Victory Capital Management Inc. reduced its position in shares of Integer Holdings Corporation (NYSE:ITGR - Free Report) by 72.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 143,468 shares of the medical equipment provider's stock after selling 371,225 shares during the period. Victory Capital Management Inc. owned approximately 0.41% of Integer worth $16,931,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Capital Research Global Investors increased its holdings in shares of Integer by 16.0% during the fourth quarter. Capital Research Global Investors now owns 1,410,803 shares of the medical equipment provider's stock worth $186,960,000 after buying an additional 194,895 shares in the last quarter. Loomis Sayles & Co. L P increased its holdings in shares of Integer by 3.8% during the fourth quarter. Loomis Sayles & Co. L P now owns 558,715 shares of the medical equipment provider's stock worth $74,041,000 after buying an additional 20,688 shares in the last quarter. Congress Asset Management Co. increased its holdings in shares of Integer by 4.9% during the first quarter. Congress Asset Management Co. now owns 522,656 shares of the medical equipment provider's stock worth $61,679,000 after buying an additional 24,306 shares in the last quarter. Driehaus Capital Management LLC increased its holdings in Integer by 5.5% in the fourth quarter. Driehaus Capital Management LLC now owns 451,464 shares of the medical equipment provider's stock valued at $59,828,000 after purchasing an additional 23,706 shares during the period. Finally, Northern Trust Corp increased its holdings in Integer by 14.2% in the fourth quarter. Northern Trust Corp now owns 422,380 shares of the medical equipment provider's stock valued at $55,974,000 after purchasing an additional 52,556 shares during the period. 99.29% of the stock is currently owned by institutional investors and hedge funds.

Integer Stock Performance

Shares of NYSE ITGR traded up $1.07 during midday trading on Friday, reaching $108.17. The company's stock had a trading volume of 614,623 shares, compared to its average volume of 474,587. Integer Holdings Corporation has a 12-month low of $104.93 and a 12-month high of $146.36. The firm has a 50 day moving average price of $118.78 and a 200-day moving average price of $123.71. The stock has a market capitalization of $3.77 billion, a P/E ratio of 47.65, a PEG ratio of 0.92 and a beta of 0.98. The company has a debt-to-equity ratio of 0.72, a current ratio of 3.41 and a quick ratio of 2.14.

Integer (NYSE:ITGR - Get Free Report) last issued its quarterly earnings results on Thursday, July 24th. The medical equipment provider reported $1.55 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.02). Integer had a return on equity of 12.27% and a net margin of 4.61%. The company had revenue of $476.00 million for the quarter, compared to analysts' expectations of $464.37 million. During the same quarter in the previous year, the business earned $1.30 EPS. The company's revenue for the quarter was up 11.4% on a year-over-year basis. As a group, equities analysts predict that Integer Holdings Corporation will post 6.01 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have commented on the stock. Benchmark cut their price target on shares of Integer from $150.00 to $140.00 and set a "buy" rating on the stock in a research report on Friday, April 25th. Truist Financial lowered their price objective on shares of Integer from $145.00 to $137.00 and set a "buy" rating on the stock in a report on Friday. Raymond James Financial reduced their price objective on shares of Integer from $150.00 to $143.00 and set an "outperform" rating for the company in a report on Friday. KeyCorp dropped their price target on shares of Integer from $154.00 to $145.00 and set an "overweight" rating on the stock in a research report on Monday, April 21st. Finally, Wall Street Zen raised Integer from a "sell" rating to a "hold" rating in a report on Monday, May 19th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $140.25.

Insider Buying and Selling

In related news, Director Martin C. Maxwell sold 8,720 shares of the firm's stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $120.56, for a total value of $1,051,283.20. Following the completion of the transaction, the director directly owned 22,170 shares of the company's stock, valued at approximately $2,672,815.20. This trade represents a 28.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Joseph W. Dziedzic sold 338,975 shares of the firm's stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $123.17, for a total transaction of $41,751,550.75. Following the completion of the transaction, the chief executive officer directly owned 47,000 shares of the company's stock, valued at approximately $5,788,990. The trade was a 87.82% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 362,434 shares of company stock valued at $44,577,115. Company insiders own 2.16% of the company's stock.

Integer Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.